Zynerba Pharma CS (ZYNE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2022 | 12-2021 | 12-2020 | 12-2019 | 12-2018 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 50,641 | 67,808 | 59,157 | 70,063 | 59,764 |
| Receivables | 1,225 | 9,581 | 9,043 | 14,614 | 3,445 |
| TOTAL | $54,775 | $80,220 | $73,366 | $87,056 | $66,956 |
| Non-Current Assets | |||||
| PPE Net | 410 | 386 | 585 | 363 | 372 |
| Other Non-Current Assets | 336 | 566 | 105 | 346 | 0 |
| TOTAL | $746 | $952 | $691 | $709 | $372 |
| Total Assets | $55,521 | $81,172 | $74,057 | $87,765 | $67,328 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,943 | 1,799 | 2,523 | 4,741 | 4,462 |
| Accrued Expenses | 7,015 | 7,897 | 11,281 | 7,074 | 5,264 |
| TOTAL | $9,173 | $9,905 | $13,913 | $12,058 | $9,726 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 120 | 354 | 0 | 110 | 0 |
| TOTAL | $120 | $354 | $N/A | $110 | $N/A |
| Total Liabilities | $9,292 | $10,258 | $13,913 | $12,168 | $9,726 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 53,352 | 42,447 | 41,252 | 23,556 | 21,070 |
| Common Shares | 48 | 41 | 30 | 23 | 18 |
| Retained earnings | -274,517 | -239,482 | -202,173 | -150,836 | -117,892 |
| TOTAL | $46,229 | $70,913 | $60,144 | $75,597 | $57,602 |
| Total Liabilities And Equity | $55,521 | $81,172 | $74,057 | $87,765 | $67,328 |